Contents

Search

amcenestrant

Indications: - neoadjuvant therapy for estrogen receptor-positive, HER2-negative breast cancer Dosage: - 200 mg, 400 mg PO Mechanism of action: - antagonizes & degrades estrogen receptors

General

antineoplastic agent (chemotherapeutic agent)

References

  1. Shapiro M AMEERA-4: Neoadjuvant Amcenestrant vs Letrozole in Postmenopausal ER+/HER2- Breast Cancer Clinical Advances in Breast Cancer. June 30, 2022 https://www.mdalert.com/ms/cabreast/article/neoadjuvant-amcenestrant-vs-letrozole